title: The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections.
abstract: The efficacy and safety of the antibiotic loracarbef have been demonstrated in a series of 22 clinical trials involving over 9,000 patients. The data compiled from these trials indicate that loracarbef is well tolerated by the majority of patients, including children and elderly patients. Most adverse events in patients receiving loracarbef were mild and transient in nature; only 1.5% of patients discontinued therapy because of drug-related adverse events. The frequency of adverse events associated with this agent compares favorably with that reported for the other antibiotics in these trials. The most commonly reported adverse reaction in the loracarbef study group was diarrhea, but this condition occurred less frequently in patients who received loracarbef than in those treated with the comparative agents. Other gastrointestinal events, such as nausea and vomiting, were reported infrequently. Headache was the second most common adverse event reported and occurred at a slightly higher frequency in the loracarbef-treated group than in patients receiving comparative antibiotics. No clinically significant alterations in laboratory parameters or gastrointestinal flora were observed following loracarbef administration. The compiled data indicate that loracarbef is a safe therapeutic option for the treatment of a wide spectrum of bacterial infections.
authors.affiliation: Anti-Infective Division, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.
authors.forename: D G
authors.initials: DG
authors.lastname: Therasse
mesh_terms: D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003967:Diarrhea / Q000139:chemically induced* / Q000453:epidemiology; D006261:Headache / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007422:Intestines / Q000187:drug effects / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D002511:Cephalosporins; C054920:loracarbef